- Home
- CUTR vs CANF Comparison
CUTR vs CANF Comparison
Compare CUTR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUTR
- CANF
- Stock Information
- Founded
- CUTR 1988
- CANF 1994
- Country
- CUTR United States
- CANF Israel
- Employees
- CUTR N/A
- CANF N/A
- Industry
- CUTR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CUTR Health Care
- CANF Health Care
- Exchange
- CUTR Nasdaq
- CANF Nasdaq
- Market Cap
- CUTR 1.8M
- CANF 9.4M
- IPO Year
- CUTR 2004
- CANF N/A
- Fundamental
- Price
- CUTR $0.10
- CANF $1.56
- Analyst Decision
- CUTR Hold
- CANF Strong Buy
- Analyst Count
- CUTR 3
- CANF 2
- Target Price
- CUTR $3.00
- CANF $14.00
- AVG Volume (30 Days)
- CUTR 17.6M
- CANF 105.6K
- Earning Date
- CUTR 05-08-2025
- CANF 03-21-2025
- Dividend Yield
- CUTR N/A
- CANF N/A
- EPS Growth
- CUTR N/A
- CANF N/A
- EPS
- CUTR N/A
- CANF N/A
- Revenue
- CUTR $155,210,000.00
- CANF $667,000.00
- Revenue This Year
- CUTR N/A
- CANF $409.56
- Revenue Next Year
- CUTR $4.61
- CANF N/A
- P/E Ratio
- CUTR N/A
- CANF N/A
- Revenue Growth
- CUTR N/A
- CANF N/A
- 52 Week Low
- CUTR $0.09
- CANF $1.29
- 52 Week High
- CUTR $3.00
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CUTR 25.08
- CANF 45.42
- Support Level
- CUTR $0.37
- CANF $1.45
- Resistance Level
- CUTR $0.24
- CANF $1.76
- Average True Range (ATR)
- CUTR 0.06
- CANF 0.12
- MACD
- CUTR -0.03
- CANF -0.02
- Stochastic Oscillator
- CUTR 2.70
- CANF 27.59
About CUTR Cutera Inc.
Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).